174 related articles for article (PubMed ID: 28618731)
1. Impact of adjuvant treatment on oncologic outcomes in patients with stage I leiomyosarcoma of the uterus.
Boyraz G; Başaran D; Salman MC; Özgül N; Yüce K
Turk J Med Sci; 2017 Jun; 47(3):841-846. PubMed ID: 28618731
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study.
Kim SI; Choi CH; Kim K; Hong DH; Park JY; Kwon BS; Lee KH; Hong DG; Shin SJ; Park SI; Kim YH; Lee SH; Lee S; Hong JH; Lee JY; Kim YB; No JH; Suh DH
J Obstet Gynaecol Res; 2020 Feb; 46(2):337-346. PubMed ID: 31814199
[TBL] [Abstract][Full Text] [Related]
4. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
5. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.
Giuntoli RL; Metzinger DS; DiMarco CS; Cha SS; Sloan JA; Keeney GL; Gostout BS
Gynecol Oncol; 2003 Jun; 89(3):460-9. PubMed ID: 12798712
[TBL] [Abstract][Full Text] [Related]
6. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
7. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience.
Mahdavi A; Monk BJ; Ragazzo J; Hunter MI; Lentz SE; Vasilev SA; Tewari KS
Int J Gynecol Cancer; 2009 Aug; 19(6):1080-4. PubMed ID: 19820372
[TBL] [Abstract][Full Text] [Related]
8. Uterine leiomyosarcoma: an updated series.
Rauh-Hain JA; Oduyebo T; Diver EJ; Guseh SH; George S; Muto MG; del Carmen MG
Int J Gynecol Cancer; 2013 Jul; 23(6):1036-43. PubMed ID: 23714705
[TBL] [Abstract][Full Text] [Related]
9. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF; Hensley ML
Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
[TBL] [Abstract][Full Text] [Related]
10. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment for uterine leiomyosarcoma.
Akers SN; Groman A; Odunsi K; Lele S; Frederick PJ
Eur J Gynaecol Oncol; 2013; 34(5):409-14. PubMed ID: 24475573
[TBL] [Abstract][Full Text] [Related]
12. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S; Dizdar O; Karakas Y; Turker A; Kars A
Curr Probl Cancer; 2018; 42(3):344-349. PubMed ID: 29576383
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
[TBL] [Abstract][Full Text] [Related]
15. Leiomyosarcoma of uterus: a review of 14 cases.
Yu KJ; Ho DM; Ng HT; Chao KC; Kan YY
Zhonghua Yi Xue Za Zhi (Taipei); 1989 Aug; 44(2):109-14. PubMed ID: 2819573
[TBL] [Abstract][Full Text] [Related]
16. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
Park JY; Park SK; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2011 Aug; 122(2):255-9. PubMed ID: 21565389
[TBL] [Abstract][Full Text] [Related]
17. Metastatic uterine leiomyosarcomas: a single-institution experience.
Bernstein-Molho R; Grisaro D; Soyfer V; Safra T; Merimsky O
Int J Gynecol Cancer; 2010 Feb; 20(2):255-60. PubMed ID: 20134269
[TBL] [Abstract][Full Text] [Related]
18. Uterine leiomyosarcoma: analysis of treatment failures and survival.
Gadducci A; Landoni F; Sartori E; Zola P; Maggino T; Lissoni A; Bazzurini L; Arisio R; Romagnolo C; Cristofani R
Gynecol Oncol; 1996 Jul; 62(1):25-32. PubMed ID: 8690287
[TBL] [Abstract][Full Text] [Related]
19. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
[TBL] [Abstract][Full Text] [Related]
20. Uterine sarcoma: clinicopathological characteristics, treatment and outcome in Iran.
Ghaemmaghami F; Karimi-Zarchi M; Gilani MM; Mousavi A; Behtash N; Ghasemi M
Asian Pac J Cancer Prev; 2008; 9(3):421-6. PubMed ID: 18990014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
